Zeniplatin is a third-generation organoplatinum compound used in cancer treatment. It is a more water-soluble organoplatinum than cisplatin. On the phase I clinical trial the most prominent non-hematological side-effect of zeniplatin was nausea and vomiting. Other non-hematological side-effects were mild or absent. Zeniplatin did not induce significant neurological or auditory toxicity. Phase II study of zeniplatin on patients with advanced ovarian cancer revealed that zeniplatin may be active in relapsing, platinum-pretreated patients, and has no direct effects on renal function as measured by isotope clearance. Despite these findings, occasional nephrotoxicity may occur in patients with compromised kidney function, even with prophylactic hydration, and thus limit the application of this new analogue. Zeniplatin has a pharmacokinetic profile similar to that of carboplatin. Zeniplatin demonstrated only modest activity in melanoma with significant gastrointestinal and hematologic toxicity.